ArticleCancer immunology, immunotherapy : CII2010

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.

Shimon Slavin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.